Literature DB >> 795015

Emepronium bromide (Cetiprin) as a postoperative spasmolytic agent in transvesical prostatectomy.

J H Syversen, E Mollestad, L S Semb.   

Abstract

To find out whether Cetiprin reduces the vesical spasms seen after cystotomias, a double-blind investigation including 22 men was carried out. Eleven of the men were given 25 mg Cetiprin i.m. twice a day for 2 days after transvesical prostatectomy, then 200 mg orally 3 times a day the following 12 days. The rest of the men, 11 patients, received placebo. In the Cetiprin group 9 patients had no vesical spasm postoperatively, whereas 1 had moderate and 1 had severe spasms. Only 4 patients were without spasms in the control group, whereas 5 had moderate and 2 severe spasms. The postoperative reduction of the bladder volume were counteracted by Cetiprin. No significant influence on liver- or kidney function was seen with the dosages mentioned.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 795015     DOI: 10.1080/21681805.1976.11882074

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  4 in total

1.  The effect of intravesically administered Cetiprin on bladder spasms after transurethral resection of the prostate. A double-blind randomized study.

Authors:  L O Henriksen; F Petersen; K R Nielsen; P Agger
Journal:  Int Urol Nephrol       Date:  1988       Impact factor: 2.370

2.  Clinical observations with Cetiprin (emepronium bromide).

Authors:  A Hamvas; I Romics; F Balogh
Journal:  Int Urol Nephrol       Date:  1981       Impact factor: 2.370

Review 3.  Current concepts in the treatment of disorders of micturition.

Authors:  K E Andersson
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

4.  The effect of parenteral emepronium bromide (Cetiprin) on postoperative vesical tenesms after transurethral resection of the prostate. A randomized, placebo-controlled study.

Authors:  L Jørgensen; H Willumsen; J R Lautorp; B Paaschburg; B Kromann; J T Andersen
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.